Overview

RAD001 Plus Bevacizumab in Metastatic Melanoma

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, open label Phase II study comparing bevacizumab and everolimus in the treatment of metastatic melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborators:
Genentech, Inc.
Novartis
Treatments:
Bevacizumab
Everolimus
Sirolimus